Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Traws Pharma ( (TRAW) ) is now available.
Traws Pharma announced positive interim results from a Phase 2 trial of ratutrelvir, a ritonavir-free oral COVID-19 treatment, on December 17, 2025. The data highlighted a favorable safety profile, no viral rebounds, and potential benefits for patients ineligible for Paxlovid due to contraindications, as well as its potential role in Long COVID prevention. With a differentiated clinical profile, this investigational treatment positions Traws Pharma as a key contender in the multi-billion-dollar COVID-19 therapeutic market.
The most recent analyst rating on (TRAW) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company focused on developing antiviral therapies to combat respiratory viral diseases, including COVID-19, Long COVID, bird flu, and seasonal influenza. Its pipeline includes novel oral antiviral agents such as ratutrelvir, which targets SARS-CoV-2 without the need for ritonavir, and tivoxavir marboxil for influenza treatment.
Average Trading Volume: 325,524
Technical Sentiment Signal: Sell
Current Market Cap: $17.58M
Learn more about TRAW stock on TipRanks’ Stock Analysis page.